A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma
Abstract Background Lineage plasticity in prostate cancer primarily induces transdifferentiation of adenocarcinoma into neuroendocrine prostate cancer (NEPC). Lineage alteration is largely driven by epigenome and is potentially reversible. Nonetheless, evidence supporting NEPC reversibility is lacki...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Cancer Medicine |
| Online Access: | https://doi.org/10.1002/cam4.70047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030945094074368 |
|---|---|
| author | Tomohiro Fukui Kosuke Okasho Yukiko Okuno Maki Fujiwara Kensuke Hikami Arinobu Fukunaga Takuro Sunada Yuki Kita Takayuki Sumiyoshi Takayuki Goto Ryoichi Saito Osamu Ogawa Takashi Kobayashi Shusuke Akamatsu |
| author_facet | Tomohiro Fukui Kosuke Okasho Yukiko Okuno Maki Fujiwara Kensuke Hikami Arinobu Fukunaga Takuro Sunada Yuki Kita Takayuki Sumiyoshi Takayuki Goto Ryoichi Saito Osamu Ogawa Takashi Kobayashi Shusuke Akamatsu |
| author_sort | Tomohiro Fukui |
| collection | DOAJ |
| description | Abstract Background Lineage plasticity in prostate cancer primarily induces transdifferentiation of adenocarcinoma into neuroendocrine prostate cancer (NEPC). Lineage alteration is largely driven by epigenome and is potentially reversible. Nonetheless, evidence supporting NEPC reversibility is lacking in materials derived from clinical specimens. Hence, we established KUCaP13, a novel NEPC cell line derived from the tissue of a patient initially diagnosed with adenocarcinoma, which later recurred as NEPC. We aimed to prove the reversibility of cellular lineage by high‐throughput chemical screening using KUCaP13 cells. Methods Compounds responsible for androgen receptor (AR) re‐expression in KUCaP13 cells were screened. A reporter gene, androgen response element luciferase (AREluc), was transduced into KUCaP13 cells to detect AR activity using luciferase assay. Results Positive control cells (KUCaP13_AREluc_AR) overexpressing AR showed enhanced luminescence upon administration of synthetic androgen. An initial screen of 1552 compounds revealed 30 candidate molecules potentially enhancing luciferase luminescence. In the second screening, we eliminated false positives and validated the findings using luciferase assay and quantitative real‐time polymerase chain reaction. However, all hit compounds were confirmed as false positives, probably due to their inhibitory activity on luciferase. Conclusions We developed a highly sensitive screening system to evaluate the reversibility of plasticity in NEPC using a novel cell line. However, no compound demonstrated the ability to re‐express AR in this cell line. Nevertheless, in future studies, this screening system could prove valuable for elucidating the mechanism of lineage plasticity in NEPC and for developing novel therapies focused on reversing plasticity. |
| format | Article |
| id | doaj-art-e257bfcfaf6f498d95c1cb39ee79cd33 |
| institution | DOAJ |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-e257bfcfaf6f498d95c1cb39ee79cd332025-08-20T02:59:06ZengWileyCancer Medicine2045-76342025-03-01145n/an/a10.1002/cam4.70047A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinomaTomohiro Fukui0Kosuke Okasho1Yukiko Okuno2Maki Fujiwara3Kensuke Hikami4Arinobu Fukunaga5Takuro Sunada6Yuki Kita7Takayuki Sumiyoshi8Takayuki Goto9Ryoichi Saito10Osamu Ogawa11Takashi Kobayashi12Shusuke Akamatsu13Department of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanMedical Research Support Center, Graduate School of Medicine Kyoto University Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanDepartment of Urology Kyoto University Graduate School of Medicine Kyoto JapanAbstract Background Lineage plasticity in prostate cancer primarily induces transdifferentiation of adenocarcinoma into neuroendocrine prostate cancer (NEPC). Lineage alteration is largely driven by epigenome and is potentially reversible. Nonetheless, evidence supporting NEPC reversibility is lacking in materials derived from clinical specimens. Hence, we established KUCaP13, a novel NEPC cell line derived from the tissue of a patient initially diagnosed with adenocarcinoma, which later recurred as NEPC. We aimed to prove the reversibility of cellular lineage by high‐throughput chemical screening using KUCaP13 cells. Methods Compounds responsible for androgen receptor (AR) re‐expression in KUCaP13 cells were screened. A reporter gene, androgen response element luciferase (AREluc), was transduced into KUCaP13 cells to detect AR activity using luciferase assay. Results Positive control cells (KUCaP13_AREluc_AR) overexpressing AR showed enhanced luminescence upon administration of synthetic androgen. An initial screen of 1552 compounds revealed 30 candidate molecules potentially enhancing luciferase luminescence. In the second screening, we eliminated false positives and validated the findings using luciferase assay and quantitative real‐time polymerase chain reaction. However, all hit compounds were confirmed as false positives, probably due to their inhibitory activity on luciferase. Conclusions We developed a highly sensitive screening system to evaluate the reversibility of plasticity in NEPC using a novel cell line. However, no compound demonstrated the ability to re‐express AR in this cell line. Nevertheless, in future studies, this screening system could prove valuable for elucidating the mechanism of lineage plasticity in NEPC and for developing novel therapies focused on reversing plasticity.https://doi.org/10.1002/cam4.70047 |
| spellingShingle | Tomohiro Fukui Kosuke Okasho Yukiko Okuno Maki Fujiwara Kensuke Hikami Arinobu Fukunaga Takuro Sunada Yuki Kita Takayuki Sumiyoshi Takayuki Goto Ryoichi Saito Osamu Ogawa Takashi Kobayashi Shusuke Akamatsu A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma Cancer Medicine |
| title | A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma |
| title_full | A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma |
| title_fullStr | A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma |
| title_full_unstemmed | A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma |
| title_short | A highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma |
| title_sort | highly sensitive screening system to evaluate the reversibility of neuroendocrine prostate cancer to prostate adenocarcinoma |
| url | https://doi.org/10.1002/cam4.70047 |
| work_keys_str_mv | AT tomohirofukui ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT kosukeokasho ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT yukikookuno ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT makifujiwara ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT kensukehikami ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT arinobufukunaga ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takurosunada ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT yukikita ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takayukisumiyoshi ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takayukigoto ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT ryoichisaito ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT osamuogawa ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takashikobayashi ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT shusukeakamatsu ahighlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT tomohirofukui highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT kosukeokasho highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT yukikookuno highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT makifujiwara highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT kensukehikami highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT arinobufukunaga highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takurosunada highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT yukikita highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takayukisumiyoshi highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takayukigoto highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT ryoichisaito highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT osamuogawa highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT takashikobayashi highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma AT shusukeakamatsu highlysensitivescreeningsystemtoevaluatethereversibilityofneuroendocrineprostatecancertoprostateadenocarcinoma |